Litcius/Paper detail

CD9-positive Exosomes Derived from Cancer-associated Fibroblasts Might Inhibit the Proliferation of Malignant Melanoma Cells

Naho Fujii, Masakazu Yashiro, Takaharu Hatano, Heishiro Fujikawa, Hisashi Motomura

2022Anticancer Research18 citationsDOIOpen Access PDF

Abstract

BACKGROUND/AIM: Exosomes secreted by various cells in the tumour microenvironment have been reported to be mediators of intercellular communication that play an important role in cancer progression. In this study, we aimed to investigate the effects of exosomes derived from cancer-associated fibroblasts (CAFs) on the proliferation of malignant melanoma (MM) cells and evaluated their clinicopathological significance. MATERIALS AND METHODS: Three malignant melanoma cell lines, A375, MMAc, and COLO679, and three CAFs established from malignant melanomas at stages 1a, 2b, and 3b, were used. The expression of CD9, CD63, and CD81 in CAF-derived exosomes was examined using western blotting. The effect of exosomes on the proliferative potential of cancer cells was analysed using cell counting and MTT assays. The expression of CD9, CD63, and CD81 was also immunohistochemically analysed in 90 malignant melanoma specimens. RESULTS: CAF-derived exosomes were positive for CD9 and CD63 and remarkably inhibited the proliferative capacity of A375 and MMAc cells. The five-year disease-free survival was significantly better in patients with CAF-derived CD9-positive exosomes than in CD9-negative patients. CONCLUSION: CAF-derived exosomes, especially CD9-positive exosomes, have an inhibitory effect on the proliferation of malignant melanoma cells. These findings suggest that CD9 expression in CAFs is a promising prognostic marker for patients with malignant melanoma.

Topics & Concepts

MicrovesiclesMelanomaCancer researchCell growthCancerMalignant cellsCancer-Associated FibroblastsFibroblastMedicineBiologyCell cultureImmunologyTumor cellsTumor microenvironmentmicroRNAInternal medicineGeneGeneticsExtracellular vesicles in diseaseCancer Immunotherapy and BiomarkersImmune cells in cancer